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Abstract
To investigate the contribution of glycation and oxidation reac-
tions to the modification of insoluble collagen in aging and dia-
betes, Maillard reaction products were measured in skin colla-
gen from 39 type 1 diabetic patients and 52 nondiabetic control
subjects. Compounds studied included fructoselysine (FL), the
initial glycation product, and the glycoxidation products,
N'-(carboxymethyl)lysine (CML) and pentosidine, formed
during later Maillard reactions. Collagen-linked fluorescence
was also studied. In nondiabetic subjects, glycation of collagen
(FL content) increased only 33% between 20 and 85 yr of age.
In contrast, CML, pentosidine and fluorescence increased five-
fold, correlating strongly with age. In diabetic patients, colla-
gen FL was increased threefold compared with nondiabetic
subjects, correlating strongly with glycated hemoglobin but not
with age. Collagen CML, pentosidine and fluorescence were
increased up to twofold in diabetic compared with control pa-
tients: this could be explained by the increase in glycation
alone, without invoking increased oxidative stress. There were
strong correlations among CML, pentosidine and fluorescence
in both groups, providing evidence for age-dependent chemical
modification ofcollagen via the Maillard reaction, and accelera-
tion of this process in diabetes. These results support the de-
scription of diabetes as a disease characterized by accelerated
chemical aging of long-lived tissue proteins. (J. Clin. Invest.
1993. 91:2463-2469.) Key words: aging - collagen * diabetes-
glycation * oxidation
Introduction
Glycation (nonenzymatic glycosylation) is a nonenzymatic,
posttranslational modification ofprotein, resulting from chemi-
cal reactions between glucose and primary amino groups (1).
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The major product in tissue proteins is fructoselysine (FL),'
formed by glycation of E-amino groups on lysine residues (Fig.
1). The extent of glycation of tissue proteins depends on the
ambient glucose concentration and is relatively constant with
age (2-4). However, products formed from FL in subsequent
Maillard or browning reactions accumulate gradually with ad-
vancing age in long-lived tissue proteins (2-4). These products
include N'-(carboxymethyl)lysine (CML) and N'-(carboxy-
methyl)hydroxylysine (CMhL), which are formed by oxida-
tive cleavage ofFL and glycated hydroxylysine respectively (3,
4), pentosidine, a fluorescent crosslink formed between argi-
nine and lysine residues (5-7) (Fig. 1), as well as unidentified
compounds with characteristic Maillard-type, visible wave-
length fluorescence (maxima at Ex = 328 nm, Em = 378 nm)
(4). CML, CMhL, and pentosidine have been termed "glycoxi-
dation" products (4, 8) because both glycation and free radical
oxidation reactions are required for their formation from re-
ducing sugars. The exact origin ofthese compounds, i.e., from
glucose vs. ribose (5), ascorbate (6, 7, 9), or other sugars (8), is
uncertain, although present evidence suggests that they are de-
rived exclusively from reactions between proteins and carbohy-
drates (8).
According to the "glycation hypothesis" of aging and the
pathogenesis of diabetic complications, accumulation of end-
stage products of the Maillard reaction (also known as ad-
vanced glycosylation end-products [AGE products]) alters the
structural properties oftissue proteins and reduces their suscep-
tibility to catabolism ( 10, 11 ). These changes contribute to the
aging oftissues, and when accelerated by hyperglycemia, to the
gradual development of diabetic complications. Despite the
attractiveness of this hypothesis, the only Maillard products
known to accumulate with age, i.e., CML, CMhL, and pentosi-
dine, result not from glycation alone: oxidation reactions are
also necessary for their formation (2-4, 7, 1 1 ). The develop-
ment of increased fluorescence of proteins in diabetes and ag-
ing is also enhanced by oxidation reactions, and carbohydrate-
or lipid-dependent processes may also be involved (8). These
considerations raise questions about the relative importance of
the glycation and oxidation components of glycoxidation in
the accumulation of Maillard products in tissue proteins.
To our knowledge, no previous studies have made direct
comparisons between the concentrations and relative rates of
accumulation ofthe glycoxidation products CML and pentosi-
dine in collagen from control and diabetic populations. There
is a similar lack of information on the relative contributions of
1. Abbreviations used in this paper: CMhL, N'-(carboxymethyl)hy-
droxylysine; CML, N'-(carboxymethyl)lysine; FL, fructoselysine; Hb,
hemoglobin.
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Figure 1. Structures of FL, CML,
and pentosidine. FL is the initial
product of glycation of protein. The
glycoxidation products, CML and
pentosidine, are formed by sequen-
tial glycation and oxidation reac-
tions between reducing sugars and
protein.
increased glycation vs. increased oxidation in the accumula-
tion of these products. We have attempted to address these
issues in the present study, and show that concentrations of
CML and pentosidine, and Maillard-type fluorescence, in-
crease in concert in human skin collagen with age, and that the
rate of their increase is accelerated, again in a concerted fash-
ion, in diabetes. Our data also suggest that the accelerated accu-
mulation of glycoxidation products in diabetes can be ex-
plained by hyperglycemia and increased glycation alone, with-
out invoking an increase in oxidative stress.
Our findings support the description ofdiabetes as a disease
characterized by accelerated chemical modification and aging
of collagen via the Maillard reaction. The relationships be-
tween concentrations ofthese biomarkers and the presence and
severity of complications in diabetes are considered in the fol-
lowing article ( 12).
Methods
Diabetic patients and control subjects. A total of 91 people were
enrolled in this study: 39 patients (27 male, 12 female) with insulin-de-
pendent (type 1) diabetes mellitus, aged 17-73 yr (41.1±15.3 yr,
mean±SD), duration ofdiabetes 0-46 yr ( 17.9±11.5 yr), and 52 nondi-
abetic control subjects, aged 0-85 yr (47.6±25.9 yr). The nondiabetic
control skin samples were obtained from healthy, nondiabetic donors,
or at autopsy at the Royal Victoria Hospital in Belfast, Northern Ire-
land. Autopsy samples were taken within 6 h of death from patients
who had died of acute illness, e.g., stillbirth, severe congenital heart
disease, trauma, or myocardial infarction. These patients had no his-
tory of diabetes and, where possible, had documented normal plasma
glucose levels during their terminal illnesses. Some analytical data on
the control patients (skin collagen FL and CML concentrations) have
been reported previously (3). Live participants in each group were
healthy and free of ailments known to elicit inflammatory responses,
such as infection, the inflammatory arthritides, or hemochromatosis.
Clinical characterization of the diabetic patients and their complica-
tion status are presented in the following article ( 12).
Skin samples. An elliptical full-thickness skin biopsy (- 0.5 x 1.0
cm) was taken from the medial aspect of the buttock (under 2% lido-
caine local anesthesia in live donors). For - 15% ofthe samples, insuf-
ficient collagen was available to perform all assays. Thus, the number
ofsamples in some analyses may not always be equal to the number of
people involved in the study. Informed consent was obtained from all
participants, and the study was approved by the Ethical and Human
Subjects Committees of the participating institutions.
Materials. Unless otherwise indicated, reagents were ofthe highest
quality obtainable from Sigma Chemical Co. (St. Louis, MO). The
preparation of FL, CML, and pentosidine standards have been de-
scribed previously (3, 7).
Analytical procedures. Procedures for sample storage, for isolation
of insoluble collagen by extraction with I M NaCl, 0.5 M acetic acid,
and organic solvents, and for acid hydrolysis ofthe collagen have been
described previously (3). FL, CML, and lysine in collagen hydrolysates
were measured as their N-trifluoroacetyl methyl esters by selected ion
monitoring gas chromatography-mass spectrometry, as described pre-
viously (3). Amounts of FL and CML were normalized to the lysine
content of the collagen by external standardization ( 13) using calibra-
tion curves generated from solutions with constant lysine content and
variable concentrations ofthe other analytes. Samples were analyzed in
random order without knowledge of the sample identity. Pentosidine
was measured in collagen hydrolysates by reversed-phase HPLC using
postcolumn fluorescence detection (Ex = 328 nm, Em = 378 nm), as
described previously (7). The assay was standardized with a prepara-
tion ofpentosidine labeled with [4,5-3H]lysine ofknown specific radio-
activity (7). Collagen-linked fluorescence was measured in collagen
solubilized by digestion with 2% pepsin in 0.5 M acetic acid for 24 h at
37°C. Fluorescence was measured at both Ex = 328 nm, Em = 378 nm
and Ex = 370 nm, Em = 440 nm, and normalized to the hydroxypro-
line content ofcollagen, measured according to Stegemann and Stalder
( 14), as modified by Maekawa et al. ( 15). Hemoglobin (Hb) A, was
measured by agar gel electrophoresis (Corning Medical, Halsted, En-
gland) after saline incubation to remove labile hemoglobin ( 16). In the
39 diabetic patients, HbA, (mean±1 standard deviation [SD]) was
11.4±2.4%, range 6.9-16.9%. In 24 ofthese patients, HbA1 values had
been obtained every 3 mo for 6 yr preceding the skin biopsy, as de-
scribed (12). From these results, a mean HbA, (MHbA1) was deter-
mined for each patient, and this correlated with recent HbA, (r = 0.78,
P < 0.0001). The normal laboratory range for HbA, in nondiabetic
subjects (mean±2 SD) is 3.6-7.2%.
Statistical analysis. Data are shown as means± 1 SD. Correlation
analyses were performed using the linear least squares method. Statisti-
cal data are summarized in figure legends.
Results
Glycation of collagen. In a previous study of the nondiabetic
subjects (3), a slight, but statistically significant, increase in the
extent of glycation (FL content) of skin collagen with age was
observed. As shown by the lower line in Fig. 2 (from reference
3, Fig. 4), this amounted to a 33% increase in glycation of
lysine residues in skin collagen between the ages of20 and 85 yr
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Figure 2. Effects of age and diabetes on glycation ofhuman skin col-
lagen. The equation of the line for control subjects aged > 20 yr (not
shown) is: mmol FL/mol Lys = [0.029 x age (yr)] + 3.27, (r = 0.54,
P < 0.001 ). There was no significant relationship between age and
skin collagen glycation in the diabetic patients.
(r = 0.55, P < 0.001). The upper line in Fig. 2 illustrates that
glycation of collagen from the diabetic patients was increased
approximately threefold compared with collagen from the non-
diabetic control subjects. In the diabetic group, collagen glyca-
tion did not correlate either with age or duration ofdiabetes (P
> 0.05). There was a significant correlation between collagen
glycation and HbAI in these patients (r = 0.74, P < 0.0001, n
= 37), confirming the results of previous studies ( 17, 18): this
correlation was strengthened when MHbAI was used in the
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Figure 4. Effects of age and diabetes on the concentration ofCML in
human skin collagen. The equation of the line for control subjects
is: mmol CML/mol Lys =[0.0 18 x age] - 0.022 (r = 0.89, P
< 0.001); and for the diabetic patients: mmol CML/mol Lys
= [0.027 X age]) - 0.015 (r =0.84, P < 0.001).
Glycoxidation products andfluorescence. In previous stud-
ies, we have shown that, in contrast to FL, there is a substantial
age-dependent increase in the concentration of CML in skin
collagen from control subjects (3), i.e., about a fivefold in-
crease between the ages of20 and 80 yr. As shown in Fig. 4, the
concentration ofCML also increases with age in collagen from
diabetic subjects, but levels ofCML in collagen from diabetic
subjects are significantly greater than those found in nondia-
betic subjects. Analyses for pentosidine (Fig. 5) and fluores-
cence (Fig. 6) also showed substantial age-dependent increases,
with higher levels in collagen from diabetic, compared with
age-matched nondiabetic, subjects. To determine the signifi-
cance ofthe differences between the two groups, each measure-















Figure 3. Skin collagen glycation (FL content) in the diabetic popu-
lation correlates strongly with mean percent glycation ofhemoglobin
(MHbA,), an index ofglycemic control over 6 yr before skin biopsy
(r = 0.89, P < 0.0001, n = 23). The ellipse in the lower left hand
corner of the graph indicates the means (± 1 SD) of measurements of
glycation of collagen (Fig. 2) and percent HbA, from adult nondia-
betic control subjects. Control HbAI values were obtained from the
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Figure 5. Effects of age and diabetes on the concentration of pentosi-
dine in human skin collagen. The equation of the line for control
subjects is: gmol pentosidine/mol Lys = [0.41 x age] - 0.48 (r
= 0.78, P < 0.001); and for the diabetic patients: Amol pentosidine/
mol Lys = [0.93 x age] - 10.27 (r = 0.83, P < 0.001).
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Figure 6. Effects of age and diabetes on Maillard-type fluorescence
(Ex = 328 nm, Em = 378 nm) in human skin collagen. The equation
of the line for the control subjects is: fluorescence units/jig Hyp
= [0.032 x age] + 0.056 (r = 0.92, P < 0.001 ); and for the diabetic
patients: fluorescence units/,ug Hyp = [0.047 x age] - 0.047 (r
=0.86,P<0.001).
predicted value for a control subject of the same age, obtained
from the regression line for the control population (Figs. 4-6).
By these analyses (Fig. 7), the control and diabetic populations
differed significantly in age-corrected levels of FL, CML, pen-
tosidine, and fluorescence in skin collagen (P < 0.001). In
contrast to FL, concentrations ofCML and pentosidine, and
also fluorescence, correlated significantly with duration of dia-
betes (CML r = 0.74; pentosidine r = 0.77; fluorescence r
= 0.71, P < 0.001); these correlations persisted to varying de-
grees when the concentrations were standardized for age
(CMLR r = 0.34, P < 0.05; pentosidineR r = 0.75, P < 0.001;
fluorescenceR r = 0.58, P < 0.01).
The strong correlations among the various Maillard prod-
ucts in the control and diabetic populations are summarized in
Fig. 8. The correlations between fluorescence and pentosidine
in both groups (Fig. 8, top panel) are consistent with the obser-
vation that pentosidine accounts for - 30% ofthe fluorescence
in collagen at Ex = 328 nm, Em = 378 nm (4, 7). There were
equally strong correlations between levels ofthe two glycoxida-
tion products, CML and pentosidine, in collagen from both the
control and diabetic groups (Fig. 8, bottom panel). Similarly,
the correlations between CML and fluorescence (graph not
shown) were highly significant for both groups (control r
= 0.94, P < 0.001; diabetic r = 0.95, P < 0.001).
Choice offluorescence maxima. In many reports on "Mail-
lard-type" fluorescence in proteins, measurements are con-
ducted at excitation and emission wavelengths of 370 and 440
nm, respectively. The recent work identifying pentosidine as a
major Maillard reaction fluorophore (5, 7) and three-dimen-
sional fluorescence spectra of proteins browned by glucose (4,
8) both suggest that the fluorescence characteristic ofthe Mail-
lard reaction has excitation and emission maxima close to the
maxima for pentosidine, i.e., 328 and 378 nm, respectively. As
illustrated in Fig. 9, there is a strong correlation between fluores-
cence of collagen at Ex/Em = 370/440 and that at Ex/Em
= 328/378 nm. However, the fluorescence intensity is about
twice as great at Ex/Em = 328/378 nm as at Ex/Em = 370/
440 nm, providing a twofold increase in sensitivity for measure-
ment of Maillard-type fluorescence in collagen if these wave-
lengths are used.
Discussion
Glycation ofprotein in diabetes and aging. The present data
show that glycation ofcollagen (FL content) is increased about
threefold in type I, insulin-dependent diabetic patients com-
pared with age-matched nondiabetic control subjects. Glyca-
tion of skin collagen correlated with glycation of hemoglobin.
However, the correlation was stronger between collagen glyca-
tion and MHbA,, an index of average glycemia over a 6-yr
period. This provides new evidence that collagen FL may re-
flect glycemic control over a longer period oftime than HbA,,
supporting the conclusions of an earlier study (19). In that
study, we observed that the FL content of collagen in type 1
diabetic patients can be decreased by a relatively short (4 mo)
period of improved glycemic control, but the proportional de-
crease in glycation was not as great for collagen as for hemoglo-
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cence were unaffected by improved0ycemic control. In keep-
ing with the conclusion that collagen FL levels are primarily
determined by medium-term (several months [19]) average
glycemia, our data demonstrate that, again in contrast to gly-
coxidation products or fluorescence, Amadori adducts increase
only slightly with age in both control and diabetic populations.
Changes in glycoxidation (Maillard) products andfluores-
cence. Comparative analyses of CML, pentosidine, and Mail-
lard-type fluorescence in skin collagen (Figs. 4-6 ) indicate that
both glycoxidation and fluorescence are increased in collagen
from diabetic patients, compared with age-matched nondia-
betic controls. The age-normalized data in Fig. 7 also indicate
significant differences between the diabetic and control popula-
tions in all parameters, independent of age. These results sug-
gest that the increased accumulation of pentosidine (as well as
CML and fluorescence) is not confined to a subset of diabetic
patients with renal complications, as has been suggested ( I11),
but rather that it is a general feature ofthe disease process. The
comparisons in Fig. 8 emphasize the strong correlations among
these three parameters of chemical damage to collagen. The
fact that CML and pentosidine are so dissimilar in their struc-
ture and physical properties, yet increase in concert both with
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Figure 9. Fluorescence in skin collagen at Ex = 328 nm, Em = 378
nm, compared to Ex = 370 nm, Em = 440 nm.
glycoxidation reactions. Because the age-dependent rate of
chemical modification of skin collagen, as measured by the
accumulation of glycoxidation products, is accelerated in the
diabetic patients, diabetes may be properly described as a dis-
ease characterized, at the chemical level, by accelerated aging
of collagen. Although CML and pentosidine are only two out
ofmany, as yet unidentified, products ofthe Maillard reaction,
they may be regarded as "biomarkers" of the overall extent of
glycoxidative aging of proteins (8) in both nondiabetic and
diabetic populations.
Role ofoxidative stress. In recent work from several labora-
tories (8, 20-24), oxidative stress and increased oxidative dam-
age to biomolecules have been proposed as possible unifying
mechanisms for the development ofcomplications in diabetes.
Although the level of glycoxidative damage to collagen is
clearly increased in the diabetic patients (Fig. 7), an important
question that can be asked from our data is whether the in-
creased levels of glycoxidation products in collagen can be at-
tributed solely to the increase in glycation, or whether an in-
crease in oxidative stress is also involved. For this reason we
have attempted to predict the levels of glycoxidation products
and fluorescence in our diabetic patients, based on the age of
onset and duration of diabetes, and the relative increase in
glycemia. The assumption is made that Maillard products ac-
cumulated in collagen at a "normal" rate until the onset of
diabetes, and thereafter at an accelerated rate, the difference
being directly proportional to the increase in glycation of pro-
tein, either collagen or hemoglobin. The age ofonset and dura-
tion ofdiabetes were known for each patient, and we used each
patient's relative increase in glycation of either collagen or he-
moglobin, compared to age-matched controls, at the time of
biopsy as an indicator of long-term glycemic control. The fol-
lowing formula was used for the calculations:
PL = CR[AO + (RG X D)], (1)
where PL = predicted level ofglycoxidation product or fluores-
cence; CR = control rate ofaccumulation (per year) ofglycoxi-
dation product or fluorescence in collagen, i.e., slope ofcontrol
(lower) line in Figs. 4-6;AO = age ofonset ofdiabetes (years);
RG = ratio ofglycation ofcollagen or hemoglobin (%HbA,) in
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the patient, compared with age-matched nondiabetic control
subject; D = duration of diabetes (years).
From these calculations, ratios of observed (actual) to pre-
dicted values for each parameter were calculated. As shown in
Table I, the observed levels of each glycoxidation product and
fluorescence in diabetic skin collagen were consistently lower
than predicted. The underestimate was more marked when
based on the relative increase in glycation of collagen than
hemoglobin in diabetic patients. Also, the underestimate re-
mained if mean HbA, values (calculated from results obtained
every 3 mo over a 6-yr period preceding the skin biopsy) were
used in the calculation. Thus, in all cases, observed levels were
lower than would be expected. We conclude that the increased
accumulation of glycoxidation products and fluorescence in
diabetic skin collagen can be explained, on average, solely by
the increase in glycation for the duration of disease: we have
found no evidence of a general increase in oxidative stress in
diabetes. Indeed, the lower than expected levels of glycoxida-
tion products and fluorescence, i.e., the ratios of< 1.0 in Table
I, suggest that oxidative stress may actually be decreased, on
average, in diabetic patients. These analyses assume that CML,
pentosidine, and fluorescence are derived predominantly from
interactions between proteins and glucose (i.e., as opposed to
ribose or ascorbate), and that the increase in glycoxidation
products is related to the increase in average glycemia, as mea-
sured by the increase in glycation of proteins. The conclusions
are valid unless one assumes that the rate offormation ofCML,
pentosidine, and increased fluorescence in collagen is primarily
determined by factors other than the extent of glycation of
proteins, e.g., variations in oxidative stress and/or levels of
carbohydrates other than glucose. Although this hypothesis
cannot be excluded, and although a possible role for increased
oxidative stress has recently been emphasized by Wolff et al.
(23), we have found a strong correlation between levels of FL
and CML in urine from diabetic patients, suggesting a relation-
ship between glycation of protein and the formation ofCML
(25). Notably, in that study, we observed that the ratio ofCML
to FL was decreased in urine from diabetic, compared with
nondiabetic, subjects. Again, this is consistent with a decrease
in oxidative stress in diabetic subjects. In relation to the possibil-
ity that CML is derived to a significant extent from sources
other than glycated proteins, recent (unpublished) findings in
our laboratory have shown that plasma pentose levels are not
Table I. Ratio ofObserved to Predicted Concentrations
ofGlycoxidation Products and Fluorescence in Skin Collagen
from Diabetic Patients
Basis of calculation*





* Ratios of observed to predicted concentrations of glycoxidation
products and fluorescence. The predicted values are calculated as de-
scribed by Eq. 1 (see Discussion), using the relative increase in glyca-
tion of collagen (FL) (left column) or hemoglobin (HbA,) (right col-
umn) for individual patients (mean±SD).
increased in type 1 diabetic patients, and that in nondiabetic
guinea pigs, ascorbate supplementation does not result in in-
creased collagen FL, CML, or pentosidine content.
Regardless of the status of oxidative stress in diabetes, it is
clear that the net glycoxidative modification of collagen is in-
creased. It is also evident from the large standard deviations
shown in Table I that the ratios, based on either glycation of
collagen or hemoglobin, are not normally distributed about the
mean. This implies that, although the average ratio ofobserved
to predicted values is < 1.0, some patients have levels of gly-
coxidation products and fluorescence which are much higher
than would be predicted from duration ofdiabetes and severity
of hyperglycemia. The presence of higher than average oxida-
tive stress in these patients may be an inherent characteristic,
unrelated to the presence of diabetes. Indeed, a considerable
variation in the rates of accumulation of glycoxidation prod-
ucts with age, despite similar glycemia, is seen in the nondia-
betic population (Figs. 4-6). Diabetic individuals who are also
under high oxidative stress and are therefore rapid accumula-
tors of glycoxidation products may be particularly vulnerable
to the development of complications. The association between
levels of skin collagen glycoxidation products and complica-
tion status is discussed further in the following article.
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